This study is in progress, not accepting new patients
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Danielle Brandman
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Danielle Brandman
Associate Professor, Medicine, School of Medicine. Authored (or co-authored) 27 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- NGM Biopharmaceuticals, Inc
- ID
- NCT04210245
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- At least 160 people participating
- Last Updated